# A Phase 3a, Repeat Dose, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects

> **NCT02135692** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 339 (actual)

## Conditions studied

- Asthma

## Interventions

- **BIOLOGICAL:** Mepolizumab
- **DRUG:** SOC

## Key facts

- **NCT ID:** NCT02135692
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05-29
- **Primary completion:** 2017-10-05
- **Final completion:** 2017-10-05
- **Target enrollment:** 339 (ACTUAL)
- **Last updated:** 2019-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02135692

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02135692, "A Phase 3a, Repeat Dose, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02135692. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*